Literature DB >> 30051228

Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone.

Jun-Hong Ye1,2, Yunn-Fang Ho3,4, Angela W-F On1,5, Wen-Wen Chen5, Yen-Ming Huang1, Wei-I Huang5, Yun-Wen Tang2.   

Abstract

Background A pharmacovigilance database of real-world adverse drug reaction (ADR) reports is helpful for characterising adverse events and identifying new signals after drug approval. Objective This study aimed to analyse trends of ADR reporting in relation to liver injury and to delineate critical factors for suspected drug-related hepatotoxicity with a focus on reports associated with amiodarone. Setting The 2000-2014 Taiwan pharmacovigilance database. Method Relevant Standardized Medical Dictionary for Regulatory Activities queries were used to identify reports associated with liver injury. Information on ADR, patient characteristics, and the verbatim pertaining to amiodarone prescriptions, liver injury, comedications, and comorbidities were extracted and evaluated. Group comparisons between Hy's Law cases and Temple's Corollary cases of suspected amiodarone-related hepatotoxicity were performed. Main outcome measure Number and nature of drug-related liver injuries, particularly those associated with amiodarone. Results Of the 98,777 ADR reports over a 15-year period, 4261 (4.3%) were related to liver injury. Sixty-eight reports contained amiodarone prescriptions, but only 49 (1.1%) were eligible for further analysis. Hepatotoxic cases associated with amiodarone mostly occurred within 1 week, exhibited a hepatocellular pattern, and were more common among elderly individuals. Among 23 discernible cases, four (17.4%) recovered fully from liver injury. The critical Hy's Law cases were associated with shorter height, lower body surface area, and higher average daily doses. Conclusion This study substantiates the importance of ADR reporting. Data pertaining to drug-associated liver injury and factors associated with suspected amiodarone-related hepatotoxicity warrants continual attention in pharmacovigilance for those at risk, especially the elderly.

Entities:  

Keywords:  Adverse drug reactions; Amiodarone; Hepatotoxicity; MedDRA-coded database; Pharmacovigilance; Taiwan

Mesh:

Substances:

Year:  2018        PMID: 30051228     DOI: 10.1007/s11096-018-0698-5

Source DB:  PubMed          Journal:  Int J Clin Pharm


  32 in total

1.  Suspected drug-induced liver fatalities reported to the WHO database.

Authors:  E Björnsson; R Olsson
Journal:  Dig Liver Dis       Date:  2005-07-28       Impact factor: 4.088

2.  Acute liver injury after intravenous amiodarone: a case report.

Authors:  Andrea Verhovez; Fabrizio Elia; Alessandra Riva; Giovanni Ferrari; Franco Aprà
Journal:  Am J Emerg Med       Date:  2010-09-25       Impact factor: 2.469

3.  Hy's law: predicting serious hepatotoxicity.

Authors:  Robert Temple
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-04       Impact factor: 2.890

4.  Drug-induced liver injury: morbidity, mortality, and Hy's law.

Authors:  Arie Regev; Einar S Björnsson
Journal:  Gastroenterology       Date:  2014-05-29       Impact factor: 22.682

5.  Drug-related morbidity and mortality. A cost-of-illness model.

Authors:  J A Johnson; J L Bootman
Journal:  Arch Intern Med       Date:  1995-10-09

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.

Authors:  Paul B Watkins; Mehul Desai; Scott D Berkowitz; Gary Peters; Yves Horsmans; Dominique Larrey; Willis Maddrey
Journal:  Drug Saf       Date:  2011-03-01       Impact factor: 5.606

8.  Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model.

Authors:  M Pirovino; O Müller; T Zysset; U Honegger
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

9.  Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I.

Authors:  T A Brennan; L L Leape; N M Laird; L Hebert; A R Localio; A G Lawthers; J P Newhouse; P C Weiler; H H Hiatt
Journal:  N Engl J Med       Date:  1991-02-07       Impact factor: 91.245

Review 10.  Biomarkers in DILI: One More Step Forward.

Authors:  Mercedes Robles-Díaz; Inmaculada Medina-Caliz; Camilla Stephens; Raúl J Andrade; M Isabel Lucena
Journal:  Front Pharmacol       Date:  2016-08-22       Impact factor: 5.810

View more
  4 in total

1.  Overview of this issue: pharmacovigilance, what is new?

Authors:  Linda Gore Martin; Yolande Hanssens; Vibhu Paudyal
Journal:  Int J Clin Pharm       Date:  2018-08

2.  Acute Multi-Organ Toxicity During 24-Hour Dosing of Intravenous Amiodarone: A Case Report.

Authors:  Terrin Liwag; Kindchia Wong; Eladio Martinez; Steven Nguyen
Journal:  Cureus       Date:  2022-05-15

3.  The Advantages and Challenges of Using Real-World Data for Patient Care.

Authors:  Yunn-Fang Ho; Fu-Chang Hu; Ping-Ing Lee
Journal:  Clin Transl Sci       Date:  2019-08-27       Impact factor: 4.689

4.  Fatal acute-on-chronic liver failure in amiodarone-related steatohepatitis: a case report.

Authors:  I-J U Wu; Jia-Huei Tsai; Cheng-Maw Ho
Journal:  BMC Gastroenterol       Date:  2021-02-02       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.